Reducing Relapse In Schizophrenia Starts With Predicting Relapse

A big part of dealing with consumers with schizophrenia comes down to addressing relapse. In her presentation Introducing RASP: Relapse Assessment In Schizophrenia Patients, delivered at last month's OPEN MINDS Performance Management Institute, Heidi Waters, Ph.D., Director of Outcomes Management, Otsuka Pharmaceutical Companies, U.S. shared just how big a challenge this is. Currently, schizophrenia affects roughly one percent of the U.S. population (2.6 million adults). The annual cost for schizophrenia in the U.S. is estimated at $60 billion (see Why Schizophrenia Remains 'Top Of Mind' At Health Plans).

Dr. Waters noted that an analysis . . .